The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer.
Abstract
PURPOSE: The administration of fluorouracil (5-FU) by continuous intravenous infusion (CI) is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancer. Although more than 1,200 patients have been enrolled onto randomized trials that compared these two treatment modalities, there is still no definitive evidence of an advantage of 5-FU CI, and the magnitude of this advantage, if any, is also controversial. A meta-analysis was performed to assess this benefit in terms of tumor response and survival, and to compare the toxicity profiles of these two modalities of administration of 5-FU. DESIGN: Individual data of 1,219 patients included in six randomized trials served as the basis for this meta-analysis, which was conducted by an independent secretariat in close collaboration with the investigators. RESULTS: Tumor response rate was significantly higher in patients assigned to 5-FU CI than in patients assigned to 5-FU bolus (22% v 14%; overall response odds ratio, 0.55; 95% confidence interval [95% CI], 0.41 to 0.75; P = .0002). Overall survival was also significantly higher in patients assigned to 5-FU CI (overall hazards ratio [HR], 0.88; 95% CI, 0.78 to 0.99; P = .04), although the median survival times were close. Multivariate analyses showed that randomized treatment and performance status were the only two significant predictors of tumor response, whereas the same plus primary tumor site were independent significant predictors of survival (patients with rectal cancer did somewhat better). Grade 3 or 4 hematologic toxicity was more frequent in patients assigned to 5-FU bolus (31% v 4%; P < 10(-16)), whereas hand-foot syndrome was more frequent in the 5-FU CI group (34% v 13%; P < 10(-7)). CONCLUSION: 5-FU CI is superior to 5-FU bolus in terms of tumor response and achieves a slight increase of overall survival. The hematologic toxicity is much less important in patients who receive 5-FU CI, but hand-foot syndrome is frequent in this group of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
O'Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,136
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
Reporting on Methods in Clinical Trials
DerSimonian, R., Charette, L. J., McPeek, B., & Mosteller, F. (1982) · New England Journal of Medicine · doi:10.1056/nejm198206033062204 · Cited by 499
Seifert, P., Baker, L. H., Reed, M. L., & Vaitkevicius, V. K. (1975) · Cancer · doi:10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c · Cited by 420
Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., & Mangalik, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1303 · Cited by 359
Cited by
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J.-N., Nagorney, D. M., & McWilliams, R. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5278 · Cited by 1,339
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 632
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 606
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., Smith, D. B., Shepherd, S., Maraveyas, A., Ferry, D. R., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61087-3 · Cited by 561
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
van Kuilenburg, A. B. P. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.12.004 · Cited by 488
Fernandez, F. G., Ritter, J., Goodwin, J. W., Linehan, D. C., Hawkins, W. G., & Strasberg, S. M. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.01.024 · Cited by 465
Janjan, N. A., Khoo, V. S., Abbruzzese, J., Pazdur, R., Dubrow, R., Cleary, K. R., Allen, P. K., Lynch, P. M., Glober, G., Wolff, R., et al. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00099-1 · Cited by 458
Mismatch repair proficiency and in vitro response to 5-fluorouracil
Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S., Howell, S. B., & Boland, C. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70558-5 · Cited by 429
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Folkman, J. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00133-5 · Cited by 415
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)
Valeri, N., Gasparini, P., Braconi, C., Paone, A., Lovat, F., Fabbri, M., Sumani, K. M., Alder, H., Amadori, D., Patel, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015541107 · Cited by 382
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
Borner, M. M., Schöffski, P., de Wit, R., Caponigro, F., Comella, G., Sulkes, A., Greim, G., Peters, G. J., van der Born, K., Wanders, J., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00371-9 · Cited by 316
Pozzo, C., Basso, M., Cassano, A., Quirino, M., Schinzari, G., Trigila, N., Vellone, M., Giuliante, F., Nuzzo, G., & Barone, C. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh217 · Cited by 315
Leonard, G. D., Brenner, B., & Kemeny, N. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.349 · Cited by 314
Basis for effective combination cancer chemotherapy with antimetabolites
Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00086-3 · Cited by 301
Vascular Access in Oncology Patients
Gallieni, M., Pittiruti, M., & Biffi, R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0015 · Cited by 284
Carmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.129 · Cited by 268
Adjuvant or Palliative Chemotherapy for Colorectal Cancer in Patients 70 Years or Older
Popescu, R. A., Norman, A., Ross, P. J., Parikh, B., & Cunningham, D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2412 · Cited by 264
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Miura, K., Kinouchi, M., Ishida, K., Fujibuchi, W., Naitoh, T., Ogawa, H., Ando, T., Yazaki, N., Watanabe, K., Haneda, S., et al. (2010) · Cancers · doi:10.3390/cancers2031717 · Cited by 260
Angiogenesis Research: Guidelines for Translation to Clinical Application
Browder, T., Palmblad, J., & Folkman, J. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616197 · Cited by 259
Circadian chronotherapy for human cancers
Lévi, F. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00326-0 · Cited by 258
Folprecht, G., Cunningham, D., Ross, P., Glimelius, B., Di Costanzo, F., Wils, J., Scheithauer, W., Rougier, P., Aranda, E., Hecker, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh344 · Cited by 257
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
S-1: a promising new oral fluoropyrimidine derivative
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902729412 · Cited by 101
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., Koralewski, P., Bridgewater, J., Mainwaring, P., Wasan, H., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn638 · Cited by 62
Bonomi, A., Sordi, V., Dugnani, E., Ceserani, V., Dossena, M., Coccè, V., Cavicchini, L., Ciusani, E., Bondiolotti, G., Piovani, G., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.005 · Cited by 56
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 1998-01
- Volume
- 16
- Issue
- 1
- Pages
- 301-308
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2396646859
- Cited by
- 981
- References
- 13
- FWCI
- 26.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.